CY1109364T1 - Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες - Google Patents
Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντεςInfo
- Publication number
- CY1109364T1 CY1109364T1 CY20091100954T CY091100954T CY1109364T1 CY 1109364 T1 CY1109364 T1 CY 1109364T1 CY 20091100954 T CY20091100954 T CY 20091100954T CY 091100954 T CY091100954 T CY 091100954T CY 1109364 T1 CY1109364 T1 CY 1109364T1
- Authority
- CY
- Cyprus
- Prior art keywords
- combination containing
- cancer factors
- combretastatin
- containing combretastatin
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Παρέχεται ένα αντικαρκινικός συνδυασμός που περιλαμβάνει ένα παράγωγο στιλβίνης και μια αντικαρκινική ένωση που επιλέγεται από την ομάδα που αποτελείται από ταξάνες, αλκυλοποιητικούς παράγοντες, ατιμεταβολίτες, αλκαλοειδή vinca, επιδοφυλλοπτοξίνες, και αντιβιοτικά ως τα ενεργά συστατικά στοιχεία. Παρέχονται επίσης μέθοδοι χρήσης αυτών των φαρμακευτικών παρασκευασμάτων για τη θεραπεία των στερεών καρκινομάτων και άλλων παρόμοιων ασθενειών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27562701P | 2001-03-15 | 2001-03-15 | |
EP02732758A EP1439839B8 (en) | 2001-03-15 | 2002-03-15 | A combination comprising combretastatin and anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109364T1 true CY1109364T1 (el) | 2014-07-02 |
Family
ID=23053164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100954T CY1109364T1 (el) | 2001-03-15 | 2009-09-16 | Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες |
Country Status (38)
Country | Link |
---|---|
US (4) | US20020183266A1 (el) |
EP (1) | EP1439839B8 (el) |
JP (1) | JP4991107B2 (el) |
KR (1) | KR100849610B1 (el) |
CN (2) | CN1290504C (el) |
AR (1) | AR032989A1 (el) |
AT (1) | ATE433750T1 (el) |
AU (1) | AU2002304574B2 (el) |
BR (1) | BR0208017A (el) |
CA (2) | CA2470484C (el) |
CY (1) | CY1109364T1 (el) |
CZ (1) | CZ302451B6 (el) |
DE (1) | DE60232673D1 (el) |
DK (1) | DK1439839T3 (el) |
EA (1) | EA006316B1 (el) |
EC (1) | ECSP034766A (el) |
ES (1) | ES2327617T3 (el) |
HK (1) | HK1067039A1 (el) |
HR (1) | HRPK20030734B3 (el) |
HU (1) | HU228510B1 (el) |
IL (2) | IL157891A0 (el) |
MA (1) | MA27000A1 (el) |
ME (2) | MEP16208A (el) |
MX (1) | MXPA03007552A (el) |
NO (1) | NO332661B1 (el) |
NZ (1) | NZ527526A (el) |
PE (1) | PE20020909A1 (el) |
PL (1) | PL205728B1 (el) |
PT (1) | PT1439839E (el) |
RS (1) | RS50682B (el) |
SI (1) | SI1439839T1 (el) |
SK (1) | SK287908B6 (el) |
TN (1) | TNSN03060A1 (el) |
TW (1) | TWI306028B (el) |
UA (1) | UA75127C2 (el) |
UY (1) | UY27208A1 (el) |
WO (2) | WO2002074229A2 (el) |
ZA (1) | ZA200306789B (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69931766T2 (de) * | 1998-04-03 | 2007-05-31 | Ajinomoto Co., Inc. | Antitumorale mittel |
US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
GB0410817D0 (en) * | 2004-05-14 | 2004-06-16 | Angiogene Pharm Ltd | Vascular damaging therapy |
CN100431606C (zh) * | 2004-11-22 | 2008-11-12 | 山东蓝金生物工程有限公司 | 一种抗癌药物组合物 |
CN1319978C (zh) * | 2005-04-06 | 2007-06-06 | 西南合成制药股份有限公司 | 康布瑞汀化合物的制备方法 |
FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
US20080104512A1 (en) * | 2006-10-31 | 2008-05-01 | Motorola, Inc. | Method and apparatus for providing realtime feedback in a voice dialog system |
ES2529434T3 (es) * | 2007-11-21 | 2015-02-20 | Oxigene, Inc. | Método para tratar neoplasias hematopoyéticas |
US20090209496A1 (en) * | 2008-02-15 | 2009-08-20 | David Chaplin | Methods and compositions for enhancing the efficacy of rtk inhibitors |
FR2939665B1 (fr) * | 2008-12-12 | 2011-10-07 | Sanofi Aventis | Combinaison antitumorale associant l'ave8062a et le docetaxel |
FR2945210B1 (fr) | 2009-05-07 | 2011-07-01 | Sanofi Aventis | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
MX2012014732A (es) | 2010-06-18 | 2013-01-22 | Sanofi Sa | Una combinacion antitumoral que comprende ombrabulina un derivado de taxano y un derivado de platino. |
EP2397135A1 (en) | 2010-06-18 | 2011-12-21 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
EP2481404A1 (en) | 2010-11-15 | 2012-08-01 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
EP2407161A1 (en) | 2010-07-13 | 2012-01-18 | Sanofi | An antitumoral combination comprising ombrabulin and bevacizumab |
FR2968557A1 (fr) | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
FR2978663A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie |
FR2978662A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie |
JP2018523712A (ja) | 2015-08-18 | 2018-08-23 | マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. | 腫瘍に対する免疫調節療法を向上させる為のvdasの使用 |
US9980953B2 (en) * | 2016-09-26 | 2018-05-29 | Chong Kun Dang Pharmaceutical Corp. | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601676B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
US5731353A (en) * | 1993-09-08 | 1998-03-24 | Ajinomoto Co., Inc. | Stilbene derivatives and pharmaceutical compositions containing them |
TW325458B (en) * | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
TW334418B (en) * | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
DE69931766T2 (de) * | 1998-04-03 | 2007-05-31 | Ajinomoto Co., Inc. | Antitumorale mittel |
US6242770B1 (en) * | 1998-08-31 | 2001-06-05 | Gary Bela Bronner | Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same |
GB9903404D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
DE60031268T2 (de) * | 1999-04-14 | 2007-05-24 | Dana-Farber Cancer Institute, Inc., Boston | Verfahren und zusammansetzung zur behandlung von krebs |
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US6448030B1 (en) * | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
AU2002216029B2 (en) * | 2000-10-27 | 2006-01-05 | Pfizer, Inc. | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
WO2002056692A1 (en) * | 2000-12-22 | 2002-07-25 | Bristol-Myers Squibb Company | Methods for modulating tumor growth and metastasis |
US6466448B1 (en) * | 2001-06-11 | 2002-10-15 | Network Appliance, Inc. | Riser board retaining and air ducting structure for printed circuit boards |
-
2002
- 2002-03-08 US US10/092,508 patent/US20020183266A1/en not_active Abandoned
- 2002-03-14 UY UY27208A patent/UY27208A1/es not_active Application Discontinuation
- 2002-03-14 AR ARP020100914A patent/AR032989A1/es unknown
- 2002-03-15 SI SI200230915T patent/SI1439839T1/sl unknown
- 2002-03-15 EP EP02732758A patent/EP1439839B8/en not_active Expired - Lifetime
- 2002-03-15 ES ES02732758T patent/ES2327617T3/es not_active Expired - Lifetime
- 2002-03-15 RS YUP-713/03A patent/RS50682B/sr unknown
- 2002-03-15 HU HU0600233A patent/HU228510B1/hu not_active IP Right Cessation
- 2002-03-15 UA UA2003109292A patent/UA75127C2/uk unknown
- 2002-03-15 AU AU2002304574A patent/AU2002304574B2/en not_active Ceased
- 2002-03-15 MX MXPA03007552A patent/MXPA03007552A/es active IP Right Grant
- 2002-03-15 IL IL15789102A patent/IL157891A0/xx unknown
- 2002-03-15 NZ NZ527526A patent/NZ527526A/en not_active IP Right Cessation
- 2002-03-15 PL PL374406A patent/PL205728B1/pl not_active IP Right Cessation
- 2002-03-15 CA CA002470484A patent/CA2470484C/en not_active Expired - Fee Related
- 2002-03-15 CN CNB028065832A patent/CN1290504C/zh not_active Expired - Fee Related
- 2002-03-15 WO PCT/EP2002/003322 patent/WO2002074229A2/en not_active Application Discontinuation
- 2002-03-15 WO PCT/EP2002/006758 patent/WO2004037258A1/en active IP Right Grant
- 2002-03-15 PT PT02732758T patent/PT1439839E/pt unknown
- 2002-03-15 US US10/097,926 patent/US6933320B2/en not_active Expired - Fee Related
- 2002-03-15 CZ CZ20032476A patent/CZ302451B6/cs not_active IP Right Cessation
- 2002-03-15 DK DK02732758T patent/DK1439839T3/da active
- 2002-03-15 DE DE60232673T patent/DE60232673D1/de not_active Expired - Lifetime
- 2002-03-15 CA CA2673449A patent/CA2673449C/en not_active Expired - Fee Related
- 2002-03-15 CN CN2006101388753A patent/CN1935134B/zh not_active Expired - Fee Related
- 2002-03-15 BR BR0208017-6A patent/BR0208017A/pt not_active IP Right Cessation
- 2002-03-15 JP JP2004545736A patent/JP4991107B2/ja not_active Expired - Fee Related
- 2002-03-15 AT AT02732758T patent/ATE433750T1/de active
- 2002-03-15 SK SK1155-2003A patent/SK287908B6/sk not_active IP Right Cessation
- 2002-03-15 TW TW091104922A patent/TWI306028B/zh not_active IP Right Cessation
- 2002-03-15 ME MEP-162/08A patent/MEP16208A/xx unknown
- 2002-03-15 NO NO20034022A patent/NO332661B1/no not_active IP Right Cessation
- 2002-03-15 KR KR1020037012033A patent/KR100849610B1/ko not_active IP Right Cessation
- 2002-03-15 PE PE2002000204A patent/PE20020909A1/es not_active Application Discontinuation
- 2002-03-15 EA EA200301015A patent/EA006316B1/ru not_active IP Right Cessation
- 2002-03-15 ME MEP-2008-162A patent/ME00056B/me unknown
-
2003
- 2003-07-08 TN TNPCT/EP2002/003322A patent/TNSN03060A1/en unknown
- 2003-08-29 ZA ZA2003/06789A patent/ZA200306789B/en unknown
- 2003-09-09 MA MA27301A patent/MA27000A1/fr unknown
- 2003-09-11 IL IL157891A patent/IL157891A/en not_active IP Right Cessation
- 2003-09-12 HR HR20030734A patent/HRPK20030734B3/xx not_active IP Right Cessation
- 2003-09-12 EC EC2003004766A patent/ECSP034766A/es unknown
-
2004
- 2004-11-23 US US10/995,998 patent/US20050075295A1/en not_active Abandoned
- 2004-12-16 HK HK04109982A patent/HK1067039A1/xx not_active IP Right Cessation
-
2007
- 2007-02-21 US US11/677,178 patent/US20070149476A1/en not_active Abandoned
-
2009
- 2009-09-16 CY CY20091100954T patent/CY1109364T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109364T1 (el) | Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες | |
CY1107675T1 (el) | Φαρμακευτικα αλατα τραμαδολης | |
DE60038183D1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
ATE339406T1 (de) | Chinazoline verbindungen als heilmittel | |
EA200401019A1 (ru) | Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества | |
ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
IS6658A (is) | Ný efnasambönd | |
MXPA02002249A (es) | Composiciones farmaceuticas agradables al paladar para animales de compania. | |
IS6329A (is) | Lyf til að meðhöndla illkynja æxli | |
BR9810495A (pt) | Composição farmacêutica | |
DE60024414D1 (de) | Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen | |
FR2764889B1 (fr) | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant | |
DK1365808T3 (da) | Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743 | |
NO990833L (no) | Farmas°ytiske forbindelser | |
AR043071A1 (es) | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica | |
ATE233754T1 (de) | Diphenyl-piperidin derivate | |
ATE405568T1 (de) | Cytotoxische mittel | |
ATE424200T1 (de) | Solubilisierte topoisomerase-gift-mittel | |
AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
RU94040150A (ru) | Стабильная лиофилизированная композиция тиотепа, способ ее получения | |
AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion | |
DE69626544T2 (de) | Arzneistoffe | |
DE60214476D1 (de) | Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung anbieten | |
EA200500082A1 (ru) | Фармацевтическая композиция для чрескожной доставки физиологически активных агентов |